Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet (2014) 3.73

Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ (2016) 2.12

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J (2016) 2.09

Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. J Am Coll Cardiol (2015) 1.52

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ (2016) 1.40

Incidence, nature, and temporal trends of adverse events associated with noncardiac procedures among veterans with drug-eluting coronary artery stents. Catheter Cardiovasc Interv (2015) 1.40

Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv (2015) 1.39

The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol (2012) 1.35

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ (2015) 1.35

Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J (2015) 1.29

Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J (2014) 1.26

Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA (2015) 1.11

Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. Clin Res Cardiol (2015) 0.93

Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res (2015) 0.92

Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ (2014) 0.91

Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart (2015) 0.85

Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol (2015) 0.85

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials (2013) 0.84

Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol (2015) 0.83

Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord (2014) 0.83

Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. PLoS One (2015) 0.82

Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J (2014) 0.82

Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J (2015) 0.82

Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol (2014) 0.80

Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation: A Meta-analysis of Randomized Controlled Trials. Chin Med J (Engl) (2016) 0.79

The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stent. Catheter Cardiovasc Interv (2014) 0.79

Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Sci Rep (2015) 0.78

Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. Thrombosis (2012) 0.78

Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res (2014) 0.78

Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World J Cardiol (2014) 0.77

Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. Arch Med Sci (2013) 0.77

Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study. Chin Med J (Engl) (2015) 0.77

Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis (2013) 0.77

A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. Iran Red Crescent Med J (2015) 0.77

Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol (2015) 0.77

Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol (2016) 0.77

Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer? Cardiol Ther (2014) 0.76

Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression. Medicine (Baltimore) (2016) 0.75

Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: a meta-analysis. ScientificWorldJournal (2014) 0.75

Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord (2016) 0.75

Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. Transl Med UniSa (2014) 0.75

No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation. Circulation (2011) 0.75

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. Postepy Kardiol Interwencyjnej (2016) 0.75

Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol (2017) 0.75

New guidelines on duration of dual antiplatelet therapy in patients with coronary artery disease: what's the novelty? J Thorac Dis (2016) 0.75

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther (2015) 0.75

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Sci Rep (2016) 0.75

Treatment of a recurrent renal artery stenosis and stent fracture using a drug eluting stent in a pediatric patient. CEN Case Rep (2015) 0.75

Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS One (2016) 0.75

Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. PLoS One (2016) 0.75

Optimizing the duration of dual antiplatelet therapy after implantation of drug-eluting coronary stents. Chin Med J (Engl) (2015) 0.75

Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine. J Thorac Dis (2016) 0.75

Duration of dual antiplatelet therapy in acute coronary syndrome. Heart (2017) 0.75

New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation. Heart Vessels (2017) 0.75

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96

Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med (2010) 6.37

Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med (2008) 4.96

Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Cardiol (2011) 4.96

SOAR and the polybasic STIM1 domains gate and regulate Orai channels. Nat Cell Biol (2009) 4.73

Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol (2003) 4.35

Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27

Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet (2004) 4.16

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02

Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med (2011) 3.55

Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation (2005) 3.54

Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation (2013) 3.49

Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol (2007) 3.05

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation. Crit Care Med (2011) 2.77

Percutaneous coronary intervention for nonculprit vessels in cardiogenic shock complicating ST-segment elevation acute myocardial infarction. Crit Care Med (2014) 2.70

Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. Circ Cardiovasc Imaging (2013) 2.68

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol (2011) 2.64

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation (2013) 2.55

The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem (2003) 2.51

Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci (2006) 2.36

Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol (2006) 2.33

The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol (2008) 2.31

Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv (2009) 2.29

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol (2012) 2.28

Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 2.25

Hybrid iFR-FFR decision-making strategy: implications for enhancing universal adoption of physiology-guided coronary revascularisation. EuroIntervention (2013) 2.15

A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med (2003) 2.07

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol (2011) 2.05

Engineered Saccharomyces cerevisiae capable of simultaneous cellobiose and xylose fermentation. Proc Natl Acad Sci U S A (2010) 2.04

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ (2006) 2.01

Potential predictors of side-branch occlusion in bifurcation lesions after percutaneous coronary intervention: a coronary CT angiography study. Radiology (2014) 2.00

Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: complete 2-year follow-up of a two-center registry. Int J Cardiol (2010) 1.98

Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenoses of different locations. JACC Cardiovasc Interv (2011) 1.94

Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv (2012) 1.89

Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res (2007) 1.89

Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol (2008) 1.86

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care (2004) 1.84

Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve. Eur Heart J (2008) 1.84

Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J (2014) 1.82

Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology (2007) 1.82

Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol (2010) 1.79